Healthcare / Medical DevicesStockholm
$0.18
-0.03 (-16.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-19.9M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-72.4%
↓Gross Margin
84.9%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-174.1%
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.4M · net income $-19.5M · FCF $-19.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.4M | $11.4M | $9.0M | $854699.00 | — |
| Net Income | $-19.5M | $-19.5M | $-17.7M | $-25.4M | $-21.1M |
| EBITDA | $-16.6M | $-16.6M | $-15.4M | $-23.9M | $-20.5M |
| EPS | -0.14 | -0.14 | -0.15 | -0.27 | -0.45 |
| Gross Margin | 84.9% | 84.9% | 98.4% | -327.2% | — |
| Operating Margin | -169.1% | -169.1% | -203.9% | -3028.8% | — |
| Net Margin | -170.5% | -170.5% | -196.4% | -2968.9% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 1.38 | 1.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-19.9M | $-19.9M | $-16.5M | $-20.4M | — |
| Returns | |||||
| ROE | -72.4% | -72.4% | -51.8% | -75.3% | -75.8% |
| Valuation | |||||
| P/B | 0.89 | 0.89 | 2.90 | 1.34 | 2.64 |
| Growth & Yield | |||||
| Revenue Growth | 26.5% | 26.5% | 955.6% | — | — |
| EPS Growth | 4.9% | 4.9% | 42.9% | 41.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-80.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.15 → -0.14
Residual
-80.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.